Bavarian Nordic A/S (BAVA.CO)
DKK 151.6
(0.83%)
DKK 151.6
(0.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.05 Billion DKK | 418.8% |
| 2022 | 84.27 Million DKK | 216.33% |
| 2021 | 35.79 Million DKK | -84.56% |
| 2020 | 657.91 Million DKK | 412.19% |
| 2019 | -269.21 Million DKK | 6.65% |
| 2018 | -300.46 Million DKK | -180.52% |
| 2017 | 345.08 Million DKK | 206.18% |
| 2016 | 87.3 Million DKK | -11.28% |
| 2015 | 127.68 Million DKK | 93.47% |
| 2014 | 65.66 Million DKK | 2.5% |
| 2013 | 54.94 Million DKK | 134.03% |
| 2012 | 5.33 Million DKK | 111.76% |
| 2011 | -234.23 Million DKK | 44.61% |
| 2010 | -420.16 Million DKK | -59.1% |
| 2009 | -274.13 Million DKK | -50.87% |
| 2008 | -127.15 Million DKK | -2029.28% |
| 2007 | -36.06 Million DKK | 95.55% |
| 2006 | -174.76 Million DKK | -117.89% |
| 2005 | -84.7 Million DKK | -2.9% |
| 2004 | -54.89 Million DKK | -138.46% |
| 2003 | 214.05 Million DKK | 1094.71% |
| 2002 | -21.51 Million DKK | 76.06% |
| 2001 | -89.88 Million DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 419.54 Million DKK | 1919.55% |
| 2024 Q1 | 21.83 Million DKK | -97.93% |
| 2023 Q2 | 700.08 Million DKK | 43.85% |
| 2023 FY | - DKK | 418.8% |
| 2023 Q3 | 378.9 Million DKK | -45.88% |
| 2023 Q4 | 1.06 Billion DKK | 181.0% |
| 2023 Q1 | 486.67 Million DKK | 39.17% |
| 2022 FY | - DKK | 216.33% |
| 2022 Q3 | 227.65 Million DKK | 448.71% |
| 2022 Q1 | -74.68 Million DKK | -245.46% |
| 2022 Q2 | -65.28 Million DKK | 12.59% |
| 2022 Q4 | 349.69 Million DKK | 53.61% |
| 2021 FY | - DKK | -84.56% |
| 2021 Q1 | 8.17 Million DKK | 103.54% |
| 2021 Q2 | 2.46 Million DKK | -69.86% |
| 2021 Q3 | 63 Million DKK | 2457.18% |
| 2021 Q4 | 51.34 Million DKK | -18.51% |
| 2020 Q2 | 221.13 Million DKK | -65.89% |
| 2020 Q3 | 161.28 Million DKK | -27.06% |
| 2020 Q4 | -230.63 Million DKK | -243.0% |
| 2020 FY | - DKK | 412.19% |
| 2020 Q1 | 648.35 Million DKK | 2950.93% |
| 2019 Q1 | -83.18 Million DKK | -10.99% |
| 2019 Q2 | -79.92 Million DKK | 3.92% |
| 2019 Q3 | -73.53 Million DKK | 7.99% |
| 2019 FY | - DKK | 6.65% |
| 2019 Q4 | -22.74 Million DKK | 69.07% |
| 2018 Q2 | -93.07 Million DKK | 42.1% |
| 2018 FY | - DKK | -180.52% |
| 2018 Q1 | -160.73 Million DKK | 6.54% |
| 2018 Q4 | -74.94 Million DKK | -247.29% |
| 2018 Q3 | 50.88 Million DKK | 154.67% |
| 2017 FY | - DKK | 206.18% |
| 2017 Q3 | 450.27 Million DKK | 557.21% |
| 2017 Q2 | 68.51 Million DKK | 4083.31% |
| 2017 Q1 | -1.72 Million DKK | -101.06% |
| 2017 Q4 | -171.98 Million DKK | -138.19% |
| 2016 Q4 | 162.67 Million DKK | 17.79% |
| 2016 Q2 | -27.63 Million DKK | 82.77% |
| 2016 Q1 | -160.44 Million DKK | -678.88% |
| 2016 FY | - DKK | -11.28% |
| 2016 Q3 | 138.1 Million DKK | 599.7% |
| 2015 FY | - DKK | 93.47% |
| 2015 Q4 | 27.71 Million DKK | 140.86% |
| 2015 Q3 | -67.83 Million DKK | -149.91% |
| 2015 Q2 | 135.9 Million DKK | 82.91% |
| 2015 Q1 | 74.3 Million DKK | -54.58% |
| 2014 Q2 | -55.6 Million DKK | -443.21% |
| 2014 Q4 | 163.58 Million DKK | 2002.1% |
| 2014 Q3 | -8.6 Million DKK | 84.53% |
| 2014 FY | - DKK | 2.5% |
| 2014 Q1 | 16.2 Million DKK | -41.76% |
| 2013 Q3 | 45.3 Million DKK | 106.85% |
| 2013 Q4 | 27.81 Million DKK | -38.6% |
| 2013 FY | - DKK | 134.03% |
| 2013 Q1 | -28 Million DKK | 44.57% |
| 2013 Q2 | 21.9 Million DKK | 178.21% |
| 2012 FY | - DKK | 111.76% |
| 2012 Q4 | -50.51 Million DKK | -206.8% |
| 2012 Q3 | 47.3 Million DKK | 56.62% |
| 2012 Q2 | 30.2 Million DKK | 306.85% |
| 2012 Q1 | -14.6 Million DKK | -127.26% |
| 2011 Q4 | 53.56 Million DKK | 281.57% |
| 2011 FY | - DKK | 44.61% |
| 2011 Q1 | -105.7 Million DKK | -4.18% |
| 2011 Q2 | -121.3 Million DKK | -14.76% |
| 2011 Q3 | -29.5 Million DKK | 75.68% |
| 2010 Q2 | -32.6 Million DKK | 65.68% |
| 2010 Q1 | -95 Million DKK | -67.87% |
| 2010 Q4 | -101.46 Million DKK | 41.59% |
| 2010 FY | - DKK | -59.1% |
| 2010 Q3 | -173.7 Million DKK | -432.82% |
| 2009 Q2 | -83.1 Million DKK | -32.75% |
| 2009 Q1 | -62.6 Million DKK | 0.0% |
| 2009 FY | - DKK | -50.87% |
| 2009 Q4 | -56.59 Million DKK | -4.42% |
| 2009 Q3 | -54.2 Million DKK | 34.78% |
| 2008 FY | - DKK | -2029.28% |
| 2007 FY | - DKK | 95.55% |
| 2006 FY | - DKK | -117.89% |
| 2005 FY | - DKK | -2.9% |
| 2004 FY | - DKK | -138.46% |
| 2003 FY | - DKK | 1094.71% |
| 2002 FY | - DKK | 76.06% |
| 2001 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ALK-Abelló A/S | 913 Million DKK | -124.731% |
| Genmab A/S | 5.56 Billion DKK | 63.104% |
| Gubra A/S | -28.89 Million DKK | 7200.851% |
| Novo Nordisk A/S | 113.33 Billion DKK | 98.19% |
| Orphazyme A/S | -26.04 Million DKK | 7976.962% |
| Pharma Equity Group A/S | -24.79 Million DKK | 8373.684% |
| Zealand Pharma A/S | -651.58 Million DKK | 414.895% |